Clinical Trials Logo

Acute Myeloid Leukaemia clinical trials

View clinical trials related to Acute Myeloid Leukaemia.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04106076 Withdrawn - Clinical trials for Acute Myeloid Leukaemia

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Start date: July 11, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine the Maximum Tolerated Dose (MTD).